Cardiovascular Risk Stratification in Covid-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04555187

Acronym

CaVaR-Co19

Enrollment

1355

Registered

2020-09-18

Start date

2020-06-08

Completion date

2021-12-01

Last updated

2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Risk Factor, Covid19

Keywords

Covid19, cardiovascular risk factor, electrocardiogram, risk stratification

Brief summary

This retrospective double-cohort study seeks to: 1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and 2. Develop a method of cardiovascular risk stratification in COVID-19

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 89 Years

Healthy volunteers

Inclusion criteria

* age \>=18y * available data on Covid19 test in the electronic medical record (either positive or negative)

Exclusion criteria

* no data of Covid19 test

Design outcomes

Primary

Measure	Time frame	Description
Number and rate of persons with cardiovascular composite outcome	6 months after Covid19 test	Number and rate of persons with composite of all-cause death, critical care utilization (ICU bed), development of a life-threatening arrhythmia (ventricular tachycardia/ventricular fibrillation or sudden cardiac arrest), acute heart failure, myocardial infarction (STEMI, NSTEMI, or silent MI), or incident stroke, whichever comes first.

Secondary

Measure	Time frame	Description
Rate of all-cause death outcome	6 months after covid19 test	Rate of all-cause death outcome
Rate of cardiac arrhythmia	6 months after covid19 test	Rate of any documented cardiac arrhythmia (tachy - or brady- arrhythmia)

Countries

United States

Outcome results